

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/17/2025	10857718-00009	Date of first issue: 09/29/2022

### SECTION 1. IDENTIFICATION

Product name : Levamisole (6.5%) / Oxyclozanide (13%) Formulation  
Other means of identification : COOPERS NILZAN LV ORAL DRENCH (36089)

#### Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc  
Address : 37 McCarville Street  
Charlottetown, PE C1E 2A7  
Telephone : 908-740-4000  
Emergency telephone : 1-908-423-6000  
E-mail address : EHSDATASTEWARD@merck.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product  
Restrictions on use : Not applicable

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS classification in accordance with the Hazardous Products Regulations

Serious eye damage : Category 1  
Reproductive toxicity : Category 2  
Specific target organ toxicity : Category 2 (Central nervous system)  
- single exposure (Oral)  
Specific target organ toxicity : Category 2 (Brain, Liver)  
- repeated exposure  
Specific target organ toxicity : Category 2 (Blood, Testis)  
- repeated exposure (Oral)

#### GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H318 Causes serious eye damage.  
H361d Suspected of damaging the unborn child.  
H371 May cause damage to organs (Central nervous system) if swallowed.  
H373 May cause damage to organs (Brain, Liver) through prolonged or repeated exposure.  
H373 May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) For-mulation

Version 5.0      Revision Date: 06/17/2025      SDS Number: 10857718-00009      Date of last issue: 04/14/2025  
Date of first issue: 09/29/2022

### Precautionary Statements

:

#### Prevention:

P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe mist or vapors.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P280 Wear protective gloves, protective clothing, eye protection and face protection.

#### Response:

P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER.  
P308 + P311 IF exposed or concerned: Call a doctor.

#### Storage:

P405 Store locked up.

#### Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

### Other hazards

None known.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Oxyclozanide	3,3',5,5',6-Pentachloro-2'-hydroxysalicylanilide	2277-92-1	$\geq 10 - < 30$ *
Silicic acid, aluminum salt	No data available	1335-30-4	$\geq 5 - < 10$ *
Levamisole hydrochloride	No data available	16595-80-5	$\geq 5 - < 10$ *
Citric acid	2-hydroxypropane-1,2,3-tricarboxylic acid	77-92-9	$\geq 1 - < 5$ *

\* Actual concentration or concentration range is withheld as a trade secret

## SECTION 4. FIRST AID MEASURES

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version 5.0	Revision Date: 06/17/2025	SDS Number: 10857718-00009	Date of last issue: 04/14/2025 Date of first issue: 09/29/2022
----------------	------------------------------	-------------------------------	---

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention immediately.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed	: Causes serious eye damage. Suspected of damaging the unborn child. May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Chlorine compounds Nitrogen oxides (NO <sub>x</sub> )
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/17/2025	10857718-00009	Date of first issue: 09/29/2022

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe the mist or vapors. Do not swallow. Do not get in eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version 5.0      Revision Date: 06/17/2025      SDS Number: 10857718-00009      Date of last issue: 04/14/2025  
Date of first issue: 09/29/2022

Materials to avoid : Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.  
Do not store with the following product types:  
Strong oxidizing agents  
Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Oxyclozanide	2277-92-1	TWA	0.4 mg/m <sup>3</sup> (OEB 2)	Internal
Silicic acid, aluminum salt	1335-30-4	TWA	2 mg/m <sup>3</sup> (Aluminum)	CA AB OEL
		TWAEV (respirable aerosol fraction)	5 mg/m <sup>3</sup>	CA QC OEL
Levamisole hydrochloride	16595-80-5	TWA	20 µg/m <sup>3</sup> (OEB 3)	Internal
Further information: Skin				
		Wipe limit	200 µg/100 cm <sup>2</sup>	Internal

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

#### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version 5.0	Revision Date: 06/17/2025	SDS Number: 10857718-00009	Date of last issue: 04/14/2025 Date of first issue: 09/29/2022
----------------	------------------------------	-------------------------------	---

Skin and body protection	: Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: suspension
Color	: yellow
Odor	: No data available
Odor Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapor pressure	: No data available

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version 5.0	Revision Date: 06/17/2025	SDS Number: 10857718-00009	Date of last issue: 04/14/2025 Date of first issue: 09/29/2022
----------------	------------------------------	-------------------------------	---

Relative vapor density	: No data available
Relative density	: No data available
Density	: No data available
Solubility(ies) Water solubility	: No data available
Partition coefficient: n-octanol/water	: Not applicable
Autoignition temperature	: No data available
Decomposition temperature	: No data available
Viscosity Viscosity, kinematic	: No data available
Explosive properties	: Not explosive
Oxidizing properties	: The substance or mixture is not classified as oxidizing.
Molecular weight	: No data available
Particle characteristics Particle size	: Not applicable

### SECTION 10. STABILITY AND REACTIVITY

Reactivity	: Not classified as a reactivity hazard.
Chemical stability	: Stable under normal conditions.
Possibility of hazardous reactions	: Can react with strong oxidizing agents.
Conditions to avoid	: None known.
Incompatible materials	: Oxidizing agents
Hazardous decomposition products	: No hazardous decomposition products are known.

### SECTION 11. TOXICOLOGICAL INFORMATION

#### Information on likely routes of exposure

Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version 5.0	Revision Date: 06/17/2025	SDS Number: 10857718-00009	Date of last issue: 04/14/2025 Date of first issue: 09/29/2022
----------------	------------------------------	-------------------------------	---

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

### Components:

#### **Oxyclozanide:**

Acute oral toxicity : LD50 (Rat): 3,519 mg/kg  
Target Organs: Central nervous system

Acute toxicity (other routes of administration) : LDLo (sheep): 10 mg/kg  
Application Route: Intravenous

#### **Silicic acid, aluminum salt:**

Acute oral toxicity : LD50 (Rat, female): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg  
Remarks: Based on data from similar materials

#### **Levamisole hydrochloride:**

Acute oral toxicity : LD50 (Rat): 180 mg/kg  
LD50 (Mouse): 223 mg/kg  
LD50 (Rabbit): 458 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

#### **Citric acid:**

Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

#### **Skin corrosion/irritation**

Not classified based on available information.

### Components:

#### **Oxyclozanide:**

Remarks : Not classified due to lack of data.

#### **Silicic acid, aluminum salt:**



# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxytoclozanide (13%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/17/2025	10857718-00009	Date of first issue: 09/29/2022

Species	: Rabbit
Method	: OECD Test Guideline 404
Result	: No skin irritation
Remarks	: Based on data from similar materials

### Levamisole hydrochloride:

Remarks	: No data available
---------	---------------------

### Citric acid:

Species	: Rabbit
Method	: OECD Test Guideline 404
Result	: No skin irritation

### Serious eye damage/eye irritation

Causes serious eye damage.

### Components:

#### Oxytoclozanide:

Remarks	: Not classified due to lack of data.
---------	---------------------------------------

#### Silicic acid, aluminum salt:

Species	: Chicken eye
Method	: Chorioallantoic membrane vascularization assay
Result	: Irreversible effects on the eye

#### Levamisole hydrochloride:

Remarks	: No data available
---------	---------------------

#### Citric acid:

Species	: Rabbit
Result	: Irritation to eyes, reversing within 21 days
Method	: OECD Test Guideline 405

### Respiratory or skin sensitization

#### Skin sensitization

Not classified based on available information.

#### Respiratory sensitization

Not classified based on available information.

### Components:

#### Oxytoclozanide:

Routes of exposure	: Dermal
Remarks	: Not classified due to lack of data.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) For-mulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/17/2025	10857718-00009	Date of first issue: 09/29/2022

### Silicic acid, aluminum salt:

Test Type	: Local lymph node assay (LLNA)
Routes of exposure	: Skin contact
Species	: Mouse
Method	: OECD Test Guideline 429
Result	: negative

### Levamisole hydrochloride:

Remarks	: No data available
---------	---------------------

### Germ cell mutagenicity

Not classified based on available information.

### Components:

#### Oxyclozanide:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative  Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive  Test Type: Mouse Lymphoma Result: positive
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative  Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

#### Silicic acid, aluminum salt:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative  Test Type: Chromosome aberration test in vitro Result: negative Remarks: Based on data from similar materials
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) For-mulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/17/2025	10857718-00009	Date of first issue: 09/29/2022

cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

### Levamisole hydrochloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Test Type: Chromosome aberration test in vitro  
Result: negative

### Citric acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Test Type: in vitro micronucleus test  
Result: positive  
  
Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow  
cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### Oxyclozanide:

Remarks : Not classified due to lack of data.

#### Silicic acid, aluminum salt:

Species : Rat  
Application Route : Ingestion  
Exposure time : 104 weeks  
Result : negative  
Remarks : Based on data from similar materials

#### Levamisole hydrochloride:

Species : Mouse  
Application Route : Oral  
Exposure time : 2 Years  
NOAEL : 80 mg/kg body weight

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) For-mulation

Version 5.0	Revision Date: 06/17/2025	SDS Number: 10857718-00009	Date of last issue: 04/14/2025 Date of first issue: 09/29/2022
----------------	------------------------------	-------------------------------	---

Remarks : No significant adverse effects were reported

Species : Rat  
Application Route : Oral  
Exposure time : 2 Years  
NOAEL : 40 mg/kg body weight  
Remarks : No significant adverse effects were reported

### Reproductive toxicity

Suspected of damaging the unborn child.

### Components:

#### Oxyclozanide:

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat, male and female  
Application Route: Oral  
General Toxicity Parent: NOAEL: 25 - 35 mg/kg body weight  
Symptoms: Reduced body weight, No effects on embryofetal and postnatal development.  
Result: No effects on fertility.

Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
General Toxicity Parent: LOAEL: 75 - 100 mg/kg body weight  
Symptoms: Reduced body weight, No effects on embryofetal and postnatal development.  
Result: No effects on fertility.

Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight  
Result: No fetotoxicity., No teratogenic effects.

Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
General Toxicity Parent: LOAEL: 80 - 160 mg/kg body weight  
Result: No fetotoxicity., No teratogenic effects., No effects on fertility.

Effects on fetal development : Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 200 mg/kg body weight  
Result: No fetotoxicity., No teratogenic effects.

Test Type: Development  
Species: Rat

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) For-mulation

Version 5.0	Revision Date: 06/17/2025	SDS Number: 10857718-00009	Date of last issue: 04/14/2025 Date of first issue: 09/29/2022
----------------	------------------------------	-------------------------------	---

Application Route: Oral  
General Toxicity Maternal: LOAEL: 100 mg/kg body weight  
Result: No fetotoxicity., No teratogenic effects.

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 32 mg/kg body weight  
Result: Fetotoxicity., Skeletal malformations.

Reproductive toxicity - Assessment : Suspected of damaging the unborn child.

### Silicic acid, aluminum salt:

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

### Levamisole hydrochloride:

Effects on fertility : Test Type: Three-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
Result: No significant adverse effects were reported

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 20 mg/kg body weight  
Result: Fetotoxicity.

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: LOAEL: 40 mg/kg body weight  
Result: Fetotoxicity.

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

### Citric acid:

Effects on fetal development : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

### STOT-single exposure

May cause damage to organs (Central nervous system) if swallowed.

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/17/2025	10857718-00009	Date of first issue: 09/29/2022

### Components:

#### **Oxyclozanide:**

Routes of exposure	: Oral
Target Organs	: Central nervous system
Assessment	: May cause damage to organs.

#### **Citric acid:**

Assessment	: May cause respiratory irritation.
------------	-------------------------------------

### **STOT-repeated exposure**

May cause damage to organs (Brain, Liver) through prolonged or repeated exposure.  
May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.

### Components:

#### **Oxyclozanide:**

Target Organs	: Brain, Liver
Assessment	: May cause damage to organs through prolonged or repeated exposure.

#### **Levamisole hydrochloride:**

Target Organs	: Blood, Testis
Assessment	: May cause damage to organs through prolonged or repeated exposure.

### **Repeated dose toxicity**

### Components:

#### **Oxyclozanide:**

Species	: Rat
NOAEL	: 9 mg/kg
LOAEL	: 44.5 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Brain, Liver, spleen, Adrenal gland
Symptoms	: Liver effects

Species	: Dog
NOAEL	: 5 mg/kg
LOAEL	: 25 mg/kg
Application Route	: Oral
Exposure time	: 3 Months
Target Organs	: Brain, Liver
Symptoms	: blood effects, alteration in liver enzymes

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) For- mulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/17/2025	10857718-00009	Date of first issue: 09/29/2022

### Silicic acid, aluminum salt:

Species	: Rat
NOAEL	: > 100 mg/kg
Application Route	: Ingestion
Exposure time	: 104 Weeks
Remarks	: Based on data from similar materials

### Levamisole hydrochloride:

Species	: Rat
NOAEL	: 2.5 mg/kg
Application Route	: Oral
Exposure time	: 18 Months
Target Organs	: Testis

Species	: Dog
LOAEL	: 20 mg/kg
Application Route	: Oral
Exposure time	: 18 Months
Target Organs	: Blood

Species	: Dog
LOAEL	: 40 mg/kg
Application Route	: Oral
Exposure time	: 3 Months

### Citric acid:

Species	: Rat
NOAEL	: 4,000 mg/kg
LOAEL	: 8,000 mg/kg
Application Route	: Ingestion
Exposure time	: 10 Days

### Aspiration toxicity

Not classified based on available information.

### Components:

#### Oxyclozanide:

|| Not applicable

### Experience with human exposure

### Components:

#### Oxyclozanide:

Ingestion	: Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression
-----------	--

#### Levamisole hydrochloride:

Ingestion	: Symptoms: Nausea, Vomiting, Headache, Dizziness, hypo-
-----------	--

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version 5.0	Revision Date: 06/17/2025	SDS Number: 10857718-00009	Date of last issue: 04/14/2025 Date of first issue: 09/29/2022
----------------	------------------------------	-------------------------------	---

||

tension

### SECTION 12. ECOLOGICAL INFORMATION

#### Ecotoxicity

##### Components:

##### **Oxyclozanide:**

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.69 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

##### **Silicic acid, aluminum salt:**

##### **Ecotoxicology Assessment**

Chronic aquatic toxicity : No toxicity at the limit of solubility.

##### **Levamisole hydrochloride:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 37.3 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 64 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

##### **Citric acid:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,535 mg/l  
Exposure time: 24 h

#### **Persistence and degradability**

##### Components:

##### **Oxyclozanide:**

Stability in water : Hydrolysis: 50 % (156 d)  
Method: OECD Test Guideline 111

##### **Citric acid:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 97 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301B



# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) For- mulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/17/2025	10857718-00009	Date of first issue: 09/29/2022

### Bioaccumulative potential

#### Components:

##### **Oxyclozanide:**

Partition coefficient: n-octanol/water	:	log Pow: 3.99 pH: 7 Method: OECD Test Guideline 107
--	---	---

##### **Citric acid:**

Partition coefficient: n-octanol/water	:	log Pow: -1.72
--	---	----------------

### Mobility in soil

#### Components:

##### **Oxyclozanide:**

Distribution among environmental compartments	:	log Koc: 4.83 Method: OECD Test Guideline 106
---	---	--

### Other adverse effects

No data available

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### **UNRTDG**

UN number	:	UN 3082
Proper shipping name	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (oxyclozanide)
Class	:	9
Packing group	:	III
Labels	:	9
Environmentally hazardous	:	yes

#### **IATA-DGR**

UN/ID No.	:	UN 3082
Proper shipping name	:	Environmentally hazardous substance, liquid, n.o.s. (Oxyclozanide)
Class	:	9

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/17/2025	10857718-00009	Date of first issue: 09/29/2022

Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 964  
Packing instruction (passenger aircraft) : 964  
Environmentally hazardous : yes

### IMDG-Code

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Oxyclozanide)  
Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### Domestic regulation

#### TDG

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (Oxyclozanide)  
Class : 9  
Packing group : III  
Labels : 9  
ERG Code : 171  
Marine pollutant : yes(Oxyclozanide)

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

## SECTION 15. REGULATORY INFORMATION

### The ingredients of this product are reported in the following inventories:

AICS : not determined  
DSL : not determined  
IECSC : not determined

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/17/2025	10857718-00009	Date of first issue: 09/29/2022

### SECTION 16. OTHER INFORMATION

#### Full text of other abbreviations

CA AB OEL	:	Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
CA QC OEL	:	Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for air-borne contaminants
CA AB OEL / TWA	:	8-hour Occupational exposure limit
CA QC OEL / TWA EV	:	Time-weighted average exposure value

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <a href="http://echa.europa.eu/">http://echa.europa.eu/</a>
--	---	---

Revision Date	:	06/17/2025
Date format	:	mm/dd/yyyy

# SAFETY DATA SHEET

according to the Hazardous Products Regulations



## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/14/2025
5.0	06/17/2025	10857718-00009	Date of first issue: 09/29/2022

---

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8